NEW YORK (GenomeWeb) – With the launch last year of two US Food and Drug Administration-cleared mass spec microbiology platforms, microbe identification has emerged as one of clinical proteomics' most prominent success stories.

Now, recent moves by Waters and Danaher could send ripples through this corner of the field.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.